



Department of Trauma and Critical Care - University of California San 
Diego Medical Center - San Diego, CA.
jderee@ucsd.edu
Received for publication on January 21, 2008
Accepted for publication on February 18, 2008
INSIghtS INto thE rEguLAtIoN of tNf-α 
produCtIoN IN humAN moNoNuCLEAr 
CELLS: thE EffECtS of NoN-SpECIfIC 
phoSphodIEStErASE INhIbItIoN




Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. Insights into the regulation of TNF-α production in human 
mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics. 2008;63:321-8.
OBJECTIVE: The objective of this study was to determine the effect of nonspecific phosphodiesterase inhibition on transcription 
factor activation and tumor necrosis factor-alpha (TNF-α) production in lipopolysaccharide (LPS)-stimulated human mononuclear 
cells.
INTRODUCTION: The production of TNF-α following LPS stimulation is one of the key steps in bacterial sepsis and inflamma-
tion. The mechanism by which phosphodiesterase inhibition alters TNF-α production in the presence of LPS remains unclear.
METHODS: Human mononuclear cells were stimulated with LPS (1 µg/mL), in the presence and absence of Pentoxifylline (PTX; 
20 mM), a nonspecific phosphodiesterase inhibitor. Western blotting of phosphorylated cytoplasmic I-κBα, nuclear factor-κB p65 
(NF-κB), and nuclear cAMP-response element binding protein (CREB) was performed. DNA binding of NF-κB and CREB was 
verified by electrophoretic mobility shift assay. TNF-α levels were determined in the supernatant of stimulated cells in the presence 
and absence Protein kinase A inhibition by an enzyme-linked immunosorbent assay (ELISA). 
RESULTS: PTX was demonstrated to significantly reduce cytoplasmic I-κBα phosphorylation, nuclear p65 phosphorylation, 
and the DNA binding activity of NF-κB. In contrast, PTX markedly enhanced the phosphorylation and DNA binding activity of 
CREB. Cells concomitantly treated with PTX and LPS secreted similar levels of TNF-α in the presence and absence Protein kinase 
A inhibition.
DISCUSSION: The increased level of cAMP that results from phosphodiesterase inhibition affects cytoplasmic and nuclear events, 
resulting in the attenuation of NF-κB and the activation of CREB transcriptional DNA binding through pathways that are partially 
Protein kinase A-independent.
CONCLUSION: PTX-mediated phosphodiesterase inhibition occurs partially through a Protein kinase A-independent pathway 
and may serve as a useful tool in the attenuation of LPS-induced inflammation.
KEYWORDS: Sepsis. Pentoxifylline. Cyclic adenosine-3. 5-monophosphate (cAMP). cAMP-response element binding protein 
(CREB). Nuclear factor-κB (NF-κB).
INTRODUCTION
The bacterial membrane component lipopolysaccharide 
(LPS) is capable of initiating phosphorylation and activation 
of multiple host intracellular protein kinases and transcription 
factors. Transcription factor activation, which results in the 
modulation of gene transcription and protein synthesis, 
is a critical element in the defense mechanism of the host 
immune system.1,2
LPS-induced transcription factor activation has been 
shown to be a key regulator of tumor necrosis factor-α 
(TNF-α) production.3 TNF-α is a potent pro-inflammatory 
cytokine involved in a wide spectrum of cellular responses. 
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Furthermore, TNF-α synthesis can be attenuated in immune 
cells exposed to phosphodiesterase (PDE) inhibition after 
challenge by a variety of pro-inflammatory stimulants.4 The 
signaling mechanisms affected by PDE inhibition, which 
ultimately lead to the downregulation of TNF-α production, 
have not been well characterized in inflammatory cells. 
Classically, it has been demonstrated that PDE inhibition 
results in the intracellular accumulation of the second 
messenger cyclic adenosine-3,5-monophosphate (cAMP) 
and subsequent activation of Protein kinase A (PKA).5 
PKA activation then leads to the phosphorylation of the 
transcription factor cAMP-response element binding 
protein (CREB), transmission of signals into the nucleus, 
and the subsequent modulation of gene transcription.6 This 
apparently simple linear cascade does not fully explain 
the mechanism by which an elevation in the intracellular 
cAMP level exerts wide-ranging effects on multiple cellular 
functions. There is a growing body of evidence suggesting 
that cAMP may function through both PKA-dependent and 
-independent mechanisms.6-8
LPS-induced activation of the transcription factor nuclear 
factor-κB (NF-κB) has also been the focus of a great deal of 
research. It has been clearly demonstrated that agents that 
increase intracellular cAMP also inhibit NF-κB-dependent 
pro-inflammatory gene transcription, particularly of the 
TNF-α gene.9 
Controversy exists regarding the exact mechanism(s) by 
which PDE inhibition down-regulates TNF-α production. 
Possibilities include, but are not limited to, inhibition of 
NF-κB DNA binding activity, downregulation of NF-κB 
transcriptional activity, increased CREB activation, and 
competition between NF-κB and CREB for common co-
activators such as CREB binding protein (CBP). It is also 
not known whether these processes rely solely upon the 
activation of PKA. 
Therefore, the objective of the present study is to 
determine the effects of nonspecific PDE inhibition with 
1-[5-oxohexyl]-3,7-dimethylxanthine (Pentoxifylline; 
PTX) on NF-κB and CREB activation in vitro in human 
mononuclear cells. With the use of specific inhibitors, we 
also investigated the role of PKA in LPS-induced TNF-α 
production. 
MATERIALS AND METHODS
This study was approved by the Human Research 
Protections Program and the Institutional Review Board. 
Written consent to participate in the study was obtained from 
all volunteers prior to blood donation. 
Heparinized Vacutainers were purchased from Becton 
Dickinson (San Jose, CA). 1.5-mL Eppendorf centrifuge 
tubes were purchased from Fisher Scientific (Pittsburg, PA). 
Hank’s balanced salt solution (HBSS) and RPMI 1640 were 
obtained from Irvine Scientific (Santa Ana, CA). LPS from 
Escherichia coli serotype 0111:B4 and PTX were purchased 
from Sigma (St. Louis, MO). The PKA inhibitor, N-[2-((p-
bromocinnamyl)amino)ethyl]-5-isoguinolinesulfonamide-
2HCl] (H89), was purchased from Calbiochem (La Jolla, 
CA). Antibodies for phosphorylated CREB (serine 133), 
phosphorylated I-κBα (serines 32 and 36), phosphorylated 
NF-κB p65 subunit (serine 276), and secondary antibodies 
were purchased from Cell Signaling (Beverly, MA). 
Dextran T500 and Percoll were received from GE 
Healthcare/Amersham Biosciences (Piscataway, NJ). The 
enzyme-linked immunosorbent assay (ELISA) for TNF-α was 
obtained from Quantikine R&D Systems (Minneapolis, MN).
Tris-glycine and DNA retardation gels, nitrocellulose 
membranes, and western blot running buffers were obtained 
from Invitrogen (Carlsbad, CA). NE-PER® nuclear and 
cytoplasmic extraction reagents, the BCA protein reagent 
kit, the Supersignal West Pico Chemiluminescent Kit, and 
the LightShift Chemiluminescent EMSA Kit were purchased 
from Pierce (Rockland, IL). CREB and NF-κB DNA 
oligonucleotide probes were synthesized by IDT (Coralville, 
IA). Nylon membranes were purchased from Roche Applied 
Sciences (Indianapolis, IN). Western blot band quantification 
was performed with the UN-SCAN-IT Gel Digitizing 
software (Silk Scientific, Orem, UT). 
Human Peripheral Blood Mononuclear Cell Isolation 
and Stimulation
Human mononuclear cells were isolated from the 
peripheral blood of four healthy human volunteers. The 
sample size was chosen from our previously published 
work, which demonstrated reliable results.10 Cell isolation 
and all subsequent experiments were conducted under 
sterile and pyrogen-free conditions. Blood collected in 
heparin tubes was incubated with Dextran T500 and the red 
cells were sedimented for 40 minutes at room temperature. 
The resultant serum was then washed with HBSS and 
separated by Percoll gradient centrifugation according to the 
manufacturer’s instructions. Cell viability was assessed by 
trypan blue dye exclusion, with purity of greater than 95%. 
Isolated cells were resuspended in RPMI 1640 supplemented 
with 10% FBS and 5 mM HEPES at a concentration of 1 x 
107cells/mL. Each subsequent experiment listed below was 
conducted on samples of 5 x 106 cells per treatment group. 
Isolated cells were stimulated with either HBSS as a negative 
control, LPS (1 µg/mL), PTX (20 mM), or concomitant 
LPS / PTX, at the above-mentioned concentrations, for 30 
minutes at 37ºC. Cells were placed on ice for 10 minutes 
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to stop the reaction and the samples were then stored at 
-70°C for further analysis. The stimulation times and 
concentrations of LPS and PTX utilized in this study were 
determined in previous pilot studies done in our laboratory, 
which examined the effects of increasing concentrations 
of PTX on LPS-induced TNF-α production. LPS at a 
concentration of 1 µg/mL and PTX at a concentration of 
20 mM were the minimum concentrations necessary to 
produce a reproducible and reliable up-regulation and down-
regulation in TNF-α production, respectively, in quantitative 
assays (data not shown).
Effect of PTX on LPS-induced TNF-α production by 
mononuclear cells 
The concentration of TNF-α was quantitatively 
determined by ELISA in the media of cells exposed to the 
treatments described above after stimulation for up to a 
maximum of 18 hours, at 3-hour intervals. The results are 
expressed in pg/mL.
SDS-PAGE and Immunoblotting (I-κBα, NF-κB p65, 
and CREB) 
Following stimulation, PBMCs were washed with 
ice-cold PBS and centrifuged to collect a cell pellet. The 
pellet was resuspended in ice-cold SDS sample buffer 
supplemented with 100 mM dithiothreitol. Cytoplasmic 
and nuclear extracts were isolated with NE-PER nuclear 
and cytoplasmic extraction reagents with 1x Halt Protease 
Inhibitor Cocktail according to the manufacturer’s 
instructions. Protein concentrations were determined with 
the BCA protein reagent kit for each sample according 
to a standardized curve for albumin. Cell lysates were 
collected by boiling the samples in a 100ºC water bath for 
5 minutes. Ten µg of protein per sample was separated by 
SDS-polyacrylamide gel electrophoresis through 8-16% 
tris-glycine polyacrylamide gradient gels and transferred 
to nitrocellulose membranes. The membranes were blocked 
with 5% milk in Tris-buffered saline/Tween 20 (Fischer 
Scientific, Pittsburgh, PA) for 1 hour. Cytoplasmic extracts 
were incubated with phosphorylated I-κBα antibody 
(1:200), while nuclear extracts were incubated with 
either phosphorylated NF-κB p65 antibody (1:500) or 
phosphorylated CREB antibody (1:500) overnight at 4°C 
in separate experiments. The membranes were washed with 
Tris-buffered saline/Tween 20 and incubated for 1 hour at 
room temperature with the secondary antibody, horseradish 
peroxidase-linked anti-rabbit IgG diluted 1:2000 in 
blocking solution. After repeated washing of the membrane, 
the Supersignal West Pico Chemiluminescent Kit was 
applied for antibody detection per the manufacturer’s 
instructions. 
Western blot data is presented as a percentage of 
LPS stimulation. The percentage of LPS stimulation was 
calculated by dividing the mean band pixel total for each 
treatment arm divided by the mean pixel total of samples 
stimulated with LPS and multiplying by 100. Thus, LPS 
stimulation is reported as 100% and each of the treatment 
arms is reported as a percent of LPS stimulation. 
NF-κB and CREB Electrophoretic Mobility Shift Assay 
(EMSA)
The non-radioactive LightShift Chemiluminescent 
EMSA Kit was used to detect DNA-protein interactions. The 
NF-κB 3´ biotin end-labeled DNA oligonucleotide used as a 
probe for the EMSA was a 42-bp double stranded construct 
(5´ - TTGTTACAA-GGGGACTTTCCGCTGGGGACTTTC
CAGGGAGGC – 3´) containing two tandemly repeated NF-
κB binding sites (underlined). Specificity was determined by 
a competition assay with the addition of 200 molar excess 
of unlabeled double stranded NF-κB oligonucleotide. The 
CREB 3´ biotin end-labeled DNA oligonucleotide used 
as a probe for the EMSA was a 23-bp double stranded 
construct (5´- TTT TCG AGC TCTGACGTCAGA-GC – 
3´) containing the CRE consensus sequence (underlined). 
Specificity was determined by a competition assay with the 
addition of 200 molar excess of unlabeled double stranded 
CREB oligonucleotide.
Nuclear extracts (10 µg) were incubated with 5 nM NF-
κB or CREB probe (NF-kB: 1x binding buffer, 50 mM KCl, 
1 mM EDTA, 1 mM DTT, 0.1% NP40, 10% glycerol, and 50 
ng/µl poly dI-dC, CREB: 1x binding buffer, 20 mM Tris, pH 
7.5, 50 mM KCl, 1 mM EDTA, 1 mM DTT, 0.10% NP40, 
6% glycerol, 0.1 mg/mL BSA and 50 ng/µl poly dI-dC) and 
were then electrophoresed through a 6% DNA retardation gel 
at 100V for 90 minutes. The gels were electrophoretically 
transferred at 380mA for 1 hour on ice to a positively 
charged nylon membrane and immediately cross-linked for 
15 minutes with a UV transilluminator equipped with a 312 
nm bulb. Streptavidin-horseradish peroxidase conjugate and 
the LightShift Chemiluminescent Substrate were used to 
detect the biotin end-labeled DNA. The nylon membranes 
were exposed to x-ray film for 1-3 minutes for detection. 
 
Role of PKA on LPS-induced mononuclear cell TNF-α 
production
To evaluate the role of PKA on TNF-α production in 
mononuclear cells and its involvement in the attenuation 
of LPS-induced TNF-α production observed following 
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PTX treatment, H89, a specific PKA inhibitor, was utilized. 
Isolated mononuclear cells were incubated according to 
the treatment groups described above in the presence and 
absence of pretreatment with H89 (10 µM) for 1 hour at 
37ºC. The dose of H89 was chosen based on previous work 
which demonstrated specific and complete inhibition of PKA 
at this concentration.10 Since the activity of this inhibitor is 
both specific and consistent at this specified dose, we did 
not include experiments with additional PKA inhibitors 
with this set of experiments. The TNF-α concentration in 
the supernatant was measured quantitatively by ELISA. The 
results are expressed in pg/mL.
Statistical Analysis
The experimental results obtained in this study were 
derived from four separate experiments with healthy volunteer 
donors. Each assay was performed in duplicate or triplicate 
where appropriate. Data is presented as the mean ± SEM. 
Statistical differences between groups were determined by 
one-way analysis of variance (ANOVA) with a Bonferroni 
correction. Statistical significance was defined as P < 0.05.
RESULTS
The effects of PTX on LPS-induced TNF-α production
To determine the duration of PDE inhibition on TNF-α 
production after LPS stimulation, time course studies were 
conducted. In accordance with prior work, PTX had a rapid and 
sustained effect on TNF-α production in vitro (Figure 1). 
PTX decreases LPS-induced NF-κB activation
Since phosphorylation leads to ubiquitination and 
degradation of I-κBα and subsequent nuclear translocation 
of NF-κB, we first examined the effects of PTX on I-κBα. 
Cytoplasmic I-κBα phosphorylation was markedly increased 
following LPS stimulation when compared to control (100 ± 
0 vs. 20 ± 18; P < 0.05). The addition of PTX significantly 
downregulated LPS-induced I-κBα phosphorylation (P = 
0.02; Figure 2) 
In a similar fashion, nuclear NF-κB p65 phosphorylation 
was increased following LPS stimulation (100 ± 0 vs. 38 ± 
20; P < 0.01). PTX similarly decreased LPS-induced NF-κB 
p65 nuclear phosphorylation, a marker of NF-κB activation 
and nuclear translocation (100 ± 0 vs. 40 ± 6; P =0.03; 
Figure 3A).
EMSAs were then performed to verify the PTX-induced 
alterations in nuclear phosphorylation resulted in similar 
effects on the DNA binding activity of NF-κB. The addition 
of PTX to LPS-stimulated mononuclear cells resulted in 
comparable downregulation of DNA binding activity, similar 
to the observed downregulation of NF-κB phosphorylation 
(Figure 3B).
Figure 1 - Phosphodiesterase inhibition attenuates LPS-induced TNF-α 
production. Isolated human mononuclear cells (5 x 106) were incubated 
with LPS (1 µg/mL) in the presence and absence of Pentoxifylline (PTX; 20 
mM). TNF-α concentrations in supernatant were measured by ELISA (pg/
mL) up to 18 hours after stimulation (n = 4 per group). PTX downregulated 
TNF-α production by mononuclear cells in a rapid and sustained manner 
(*, P < 0.05 vs. LPS / PTX).
Figure 2 - Phosphodiesterase inhibition attenuates LPS-induced I-κBα phos-
phorylation. Isolated human mononuclear cells (5 x 106) were incubated with 
LPS (1 µg/mL) and Pentoxifylline (PTX; 20 mM). I-κBα phosphorylation 
was assessed by western blotting, as described in Materials and Methods. 
Results are expressed as a percentage of LPS stimulation ± SEM (n = 4 per 
group). LPS-stimulation markedly enhanced I-κBα phosphorylation over 
that of the control (*, P < 0.05 vs. HBSS). The addition of PTX resulted in 
a marked reduction in I-κBα phosphorylation (†, P = 0.02 vs. LPS). 
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PTX upregulates CREB phosphorylation and activation 
after LPS stimulation
Phosphorylation of nuclear CREB was used as a marker 
for CREB activation. LPS stimulation caused a negligible 
increase in CREB phosphorylation when compared to control 
(Figure 4A). PTX alone caused a marked increase in CREB 
phosphorylation (P < 0.01 vs. HBSS). When LPS and PTX 
exposure occurred simultaneously, CREB phosphorylation 
was significantly higher than with LPS stimulation alone 
(543 ± 92 vs. 100 ± 0; P < 0.01). In addition, the amount of 
CREB phosphorylation seen with concomitant LPS and PTX 
treatment was less than that seen with PTX alone, although 
this difference was not statistically significant (P = 0.08). 
To determine if CREB-DNA binding was affected by 
PTX in a manner similar to CREB phosphorylation, an 
EMSA was performed. Exposure of LPS-stimulated cells to 
PTX similarly increased CREB DNA-binding compared to 
LPS alone (Figure 4B).
Figure 3 - Effects of phosphodiesterase inhibition on LPS-induced NF-κB 
phosphorylation. Isolated human mononuclear cells (5 x 106) were incubated 
with LPS (1 µg/mL) in the presence and absence Pentoxifylline (PTX; 20 
mM). A, Nuclear NF-κB p65 phosphorylation was assessed by western blot-
ting, and results are expressed as a percentage of LPS stimulation ± SEM (n 
= 4 per group). LPS-stimulation markedly enhanced NF-κB phosphorylation 
over that of the control (*, P < 0.01 vs. HBSS). The addition of PTX resulted 
in diminished NF-κB phosphorylation (†, P = 0.03 vs. LPS). B, NF-κB 
DNA-binding was determined by EMSA, as described in Materials and 
Methods. NF-κB-DNA binding was upregulated following LPS treatment 
and attenuated following the addition of PTX in a manner that was similar 
to NF-κB p65 subunit phosphorylation. 
Figure 4. Effects of phosphodiesterase inhibition on LPS-induced CREB 
phosphorylation. Isolated human mononuclear cells (5 x 106) were incubated 
with LPS (1 µg/mL) in the presence and absence Pentoxifylline (PTX; 20 
mM). A, CREB phosphorylation was assessed by western blotting, and the 
results are expressed as a percentage of LPS stimulation ± SEM (n = 4 per 
group). Incubation of cells with PTX alone resulted in a concentration-
dependent upregulation of CREB phosphorylation (*, P < 0.05 vs. HBSS). 
The concomitant administration of LPS slightly attenuated phosphorylation, 
which nonetheless remained significant when compared to that observed in 
cells treated with LPS alone (†, P < 0.01 vs. LPS). B, CREB-DNA binding 
was determined by EMSA, as described in Materials and Methods. CREB-
DNA binding after LPS stimulation was similar to that of the control. PTX 
upregulated CREB-DNA binding in the presence and absence of LPS in a 
manner that was similar to CREB phosphorylation.
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Effect of PTX on TNF-α production in the presence of 
PKA inhibition
The role of PKA in PTX-induced downregulation of 
TNF-α production in LPS-stimulated mononuclear cells 
was assessed by treating mononuclear cells with H89, a PKA 
inhibitor, prior to LPS and PTX exposure. The addition PTX 
to LPS-stimulated cells resulted in a reduction in TNF-α, 
similar to that observed in our previous experiments (529 
pg/mL ± 112 vs. 37 pg/mL ± 10; P < 0.01). Pre-incubation 
of cells with H89 prior to LPS and PTX exposure did not 
result in any significant modulation of TNF-α production 
when compared to that demonstrated with PTX alone (P = 
0.2; Figure 5). These results suggest that downregulation of 
TNF-α production by PTX in LPS-stimulated mononuclear 
cells is, at least in part, PKA-independent. 
DISCUSSION
The exposure of inflammatory cells to a variety of 
extracellular stimuli results in the initiation of transcriptional and 
posttranscriptional events, which culminate in the production of 
pro-inflammatory mediators.11-14 TNF-α is released very early 
following shock and is considered an important mediator of the 
inflammatory cascade, since it regulates the synthesis of several 
other critical cytokines and chemokines.15 A clear relationship 
between increased TNF-α synthesis and the development of 
shock and multiple organ dysfunction has been observed in 
animal models of sepsis.15-17 
Because of its importance in orchestrating multiple steps 
of the inflammatory response, strategies aimed at decreasing 
TNF-α levels or attenuating its production seem attractive. 
PDE inhibitors have been shown to downregulate TNF-α 
production in distinct human cell populations. We have 
previously shown that, in general, TNF-α levels continue to 
increase after LPS exposure and that concomitant infusion of 
phosphodiesterase inhibitors can markedly decrease TNF-α 
levels.18-19 In this in vitro study, we verified the sustained 
attenuation of LPS-induced TNF-α expression over time in 
an isolated human mononuclear cell population.
The mechanisms by which PTX, a non-specific 
phosphodiesterase inhibitor, significantly and consistently 
decreases TNF-α production have not been completely 
elucidated. It has been postulated that drugs that increase 
intracellular cAMP exert their anti-inflammatory effects 
through the activation of PKA. This classic pathway has been 
challenged as the sole mechanism involved in the modulation 
of inflammation by cAMP-enhancing drugs, and alternative 
mechanisms involving PKA-independent pathways 
have been proposed.6-8 In this series of experiments, we 
observed a significant attenuation of TNF-α production in 
LPS-stimulated human mononuclear cells following PTX 
administration, independent of PKA activation. 
We used a nonspecific phosphodiesterase inhibitor, PTX, 
in the present study because it has been used clinically in the 
treatment of a variety of conditions in which inflammation 
is an important component of the pathophysiology of the 
disease process.19 Additionally, the use of PTX in sepsis as 
an adjunct to other treatments to maintain adequate organ 
function has been explored based upon its effects on TNF-α 
synthesis. However, the reported beneficial effects of PTX 
are not only related to the downregulation of TNF-α but 
also to PTX’s hemorrheologic properties, its ability to 
reduce neutrophil activation, and its beneficial effects on 
microcirculation, cardiac performance, and organ injury.20-25 
Herein, we demonstrated that the downregulatory effects 
of PTX in human mononuclear cells involves modulation 
of pathways that involve NF-κB and CREB, two major 
transcription factors involved in the inflammatory cascade. 
NF-κB/Rel constitutes a family of transcriptional factors 
involved in the regulation of numerous cytokine genes and 
immune responses in different cell populations. The most 
abundant form of NF-κB is the p50-p65 heterodimer.26 The 
inactive form of NF-κB exists in the cytoplasm bound to an 
inhibitory complex containing I-κBα. Following cellular 
stimulation with LPS and chemotactic factors, NF-κB 
inducible kinase phosphorylates and activates the I-κB kinase 
(IKK) complex consisting of IKK-1 and IKK-2, which in 
turn phosphorylates the I-κBα subunit. Phosphorylation, 
ubiquitination, and subsequent degradation of I-κBα 
Figure 5 - Phosphodiesterase inhibition downregulates LPS-induced TNF-α 
production independent of Protein kinase A (PKA). Isolated mononuclear 
cells (5 x 106) were preincubated with the PKA inhibitor, H89 (10 µM), for 
one hour prior to stimulation with LPS (1 µg/mL) or LPS (1 µg/mL) and 
Pentoxifylline (PTX; 20 mM) for an additional 30 minutes. The concentra-
tion of TNF-α present in the supernatant was measured by ELISA. PTX 
downregulated LPS-induced TNF-α expression (*, P < 0.01 vs. LPS). The 
addition of H89 did not significantly alter the effects of PTX on TNF-α 
production after LPS stimulation. 
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results in NF-κB nuclear translocation. This allows the 
transcription factor to bind to promoter regions of specific 
pro-inflammatory genes and influence transcription.27,28 
Because a number of potential κB sites are present in 
the nucleotide sequences of the TNF-α gene, NF-κB is 
considered to be a critical transcriptional factor involved in 
TNF-α gene expression and protein synthesis.29,30 
In this set of experiments, we demonstrated that PTX 
downregulates cytoplasmic I-κBα phosphorylation, nuclear 
NF-κB p65 phosphorylation/translocation, as well as NF-
κB DNA-binding after LPS stimulation, suggesting that 
PTX exerts its function proximal to or at the level of I-κBα 
phosphorylation. 
Previous studies that have evaluated the effects of 
cAMP-elevating drugs on I-κBα and NF-κB have reported 
conflicting results. Haddad et al. reported results similar to 
ours with respect to the effects of PTX on I-κBα and NF-κB 
in pulmonary epithelial cells.31 Conversely, Neumann et al. 
proposed that increased intracellular cAMP stabilizes the 
interaction between I-κBα and NF-κB, therefore reducing 
NF-κB activation.32 In contrast, Takahashi et al. showed no 
difference in I-κBα degradation in Jurkat T-lymphocytes in 
the presence and absence of forskolin, an alternative cAMP 
inducing compound. This group also demonstrated that 
forskolin did not inhibit the DNA-binding activity of NF-
κB and that CREB was not involved in forskolin-induced 
decrease in p65 transcriptional activity.33 Similar results were 
reported by Ollivier et al. using THP-1 cells and endothelial 
cells treated with forskolin or dibutyryl cAMP, two agents 
known to function through cAMP elevation and subsequent 
PKA activation.9 The differences between our results and 
those mentioned above may be explained by the use of 
different cell types and exogenous stimulants. It is also 
possible that PTX exerts its anti-inflammatory effects on the 
NF-κB pathway independent of PKA, as suggested by the 
continued attenuation of LPS-induced TNF-α production by 
PTX in the presence or absence of PKA inhibition observed 
in this study. This hypothesis is currently under investigation 
in our laboratory. Furthermore, we utilized a broad PKA 
inhibitor in this study in addition to H89, but did not examine 
the effect of specific inhibition of various PKA isoforms. 
This information may yield more insight into the mechanism 
by which PTX exerts its down-regulatory effects. 
PDE inhibitors may also downregulate NF-κB 
transcriptional activity by altering the competitive binding 
of CREB and NF-κB to the promoter regions of pro-
inflammatory genes. Herein, we showed that the activation 
and DNA binding activity of CREB is upregulated in a 
dose–dependent manner by PTX. Of note, the increase in 
CREB activity was slightly alleviated by the addition of 
LPS, suggesting competition between PTX-induced CREB-
associated gene transcription and those factors, such as 
NF-κB, which may be upregulated by LPS exposure. This 
competition has been postulated to involve the recruitment of 
the co-activator CBP and its homologue p30034, suggesting 
an alternative mechanism that may be involved in the anti-
inflammatory actions of PTX. Future studies are planned to 
delineate the validity of this potential mechanism.
The effects of PTX on other transcription factors, such as 
AP-1, c-fos, and c-jun, cannot be ruled out by our experiments. 
Activation of AP-1 and its components (c-fos and c-jun) by 
agents that enhance mononuclear cell activity has been 
implicated in TNF-α expression. Moreover, AP-1 and CREB 
recognize a similar DNA binding sequence in the promoter 
region of the TNF-α gene35. Given these relationships, it is 
conceivable that PTX may exert some of its anti-inflammatory 
actions by affecting AP-1 activation and favoring CREB 
binding, thus inhibiting TNF-α gene transcription. Additional 
studies are necessary to elucidate the complex interactions 
between CREB, NF-κB, and AP-1 following LPS exposure 
and PDE inhibition. Furthermore, the effect of PTX on the 
cGMP pathway after LPS stimulation has not been explored, 
although we plan to do so in the future. 
In summary, we have demonstrated that PDE inhibition 
of human mononuclear cells downregulates TNF-α 
production, at least in part, through a PKA-independent 
mechanism. In addition, PTX attenuates the activity of NF-κB 
while upregulating CREB activation after LPS stimulation, 
which may result in modulation of pro-inflammatory 
mediator synthesis. Therefore, PTX may serve as a potential 
adjunct therapeutic for the treatment of conditions in which 
TNF-α production plays a significant role.
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